Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Core Insights - Jade Biosciences, Inc. has appointed Brad Dahms as Chief Financial Officer, bringing extensive experience in guiding biotech companies through growth phases [1][2] - The company is focused on developing innovative therapies for autoimmune diseases, with its lead candidate, JADE101, targeting IgA nephropathy and expected to enter clinical trials in the second half of 2025 [3] Company Overview - Jade Biosciences specializes in creating best-in-class therapies for autoimmune diseases, with a pipeline that includes JADE101 and JADE201, as well as an undisclosed antibody discovery program, JADE-003 [3] - The company was established based on assets licensed from Paragon Therapeutics, an antibody discovery engine [3] Leadership Background - Brad Dahms has a strong track record in the biotech sector, having previously served as CFO and Chief Business Officer at IDRx, where he led the company through a significant sale to GSK for up to $1.15 billion [2] - His prior roles include CFO positions at Theseus Pharmaceuticals and Selecta Biosciences, where he was instrumental in securing financing and forming strategic partnerships [2]